Tag:
Johnson & Johnson
Latest Headlines
Latest Headlines
J&J will abandon metal hip replacement sales
Johnson & Johnson has had enough with metal-on-metal and ceramic-on-metal hips, disclosing that it will leave those business lines entirely behind by the end of 2014.
GE Healthcare releases MRI tech designed to better spot hip implant problems
GE Healthcare is unveiling new magnetic resonance imaging technique that--perhaps unintentionally--addresses an unfortunate market need created by health concerns over all-metal hip implants. In short, it helps detect implant-related problems before they become too serious.
Colitis nod puts J&J's Simponi one step closer to blockbuster
Johnson & Johnson's new-generation rheumatoid arthritis drug now has a new approval in ulcerative colitis. Simponi, which J&J developed as a follow-up to its top-selling autoimmune therapy Remicade, could leap to blockbuster status with the help of this new indication, analysts say.
Report: Roche looking to unload blood glucose meter business
Roche may be trying to unload its blood glucose meter business, reflecting continued challenges over reimbursement, and a contrast from the far better success the company has enjoyed with diagnostics development.
WSJ: J&J federal Risperdal deal hung up on language over breasts
Johnson & Johnson has been negotiating terms of a multibillion dollar settlement over aggressive marketing of its antipsychotic drug Risperdal with federal authorities for at least two years, and now it is hung on talk over breasts, The Wall Street Journal says.
J&J gains pivotal PMA for computer-aided surgical sedation device
Johnson & Johnson achieved a pivotal FDA PMA approval for what is being billed as the first computer-assisted sedation system, now available for endoscopy procedures.
J&J's propofol administration device finally wins FDA nod
Johnson & Johnson won FDA approval for its Sedasys device to administer the sedative propofol.
Indian watchdogs pull J&J plant's license on baby-powder sterilization issue
South Korean regulators have forced Johnson & Johnson to halt production at an over-the-counter drug plant, and Indian watchdogs are doing the same at a consumer healthcare facility in their country.
J&J dealing with OTC manufacturing issues on 3 continents
Prescription drugs may be more involved to make than over-the-counter products, but a manufacturing problem is a problem either way and just as likely to get a company in trouble with regulators.
J&J issue in South Korea reminiscent of OTC problems here
Drugmakers hope to export their success to emerging markets so they can reap big rewards, but Johnson & Johnson's Janssen unit appears to have taken a backward approach in South Korea, where it is in hot water over a recall of Children's Tylenol products.
